MeSH term
Frequency | Condition_Probility | Camptothecin/pharmacology | 9 | 18.0 |
Cell Line | 8 | 0.0 |
Comet Assay | 2 | 2.0 |
DNA Replication/drug effects | 2 | 1.0 |
Humans | 100 | 0.0 |
Mutation | 8 | 0.0 |
Protein Binding | 11 | 0.0 |
Research Support, Non-U.S. Gov't | 37 | 0.0 |
Animals | 31 | 0.0 |
DNA Topoisomerases, Type I/*metabolism | 17 | 62.0 |
Enzyme Inhibitors/*pharmacology | 12 | 1.0 |
Tumor Cells, Cultured | 25 | 0.0 |
Chromosomes, Human, Pair 20/*genetics | 3 | 5.0 |
Comparative Study | 14 | 0.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Base Sequence/genetics | 2 | 0.0 |
Female | 13 | 0.0 |
Middle Aged | 7 | 0.0 |
Molecular Sequence Data | 26 | 0.0 |
Antineoplastic Agents/*pharmacology | 7 | 0.0 |
Camptothecin/*pharmacology | 17 | 48.0 |
Catalysis | 4 | 0.0 |
Cell Cycle | 4 | 0.0 |
DNA/chemistry | 2 | 0.0 |
DNA Damage | 12 | 1.0 |
DNA Repair | 5 | 0.0 |
DNA Topoisomerases, Type I/*chemistry | 2 | 66.0 |
Enzyme Inhibitors/pharmacology | 9 | 0.0 |
Models, Chemical | 3 | 0.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 12 | 7.0 |
Blotting, Western | 4 | 0.0 |
Dose-Response Relationship, Drug | 10 | 0.0 |
Down-Regulation | 2 | 0.0 |
Models, Biological | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 37 | 0.0 |
Time Factors | 5 | 0.0 |
DNA Topoisomerases, Type I/*genetics | 6 | 37.0 |
Male | 10 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Base Sequence | 22 | 0.0 |
Binding Sites | 10 | 0.0 |
Oligonucleotides/chemistry | 2 | 1.0 |
Stereoisomerism | 2 | 0.0 |
Adult | 2 | 0.0 |
Aged | 3 | 0.0 |
Molecular Conformation | 2 | 0.0 |
Structure-Activity Relationship | 6 | 0.0 |
Thermodynamics | 3 | 0.0 |
*Genes, Fungal | 2 | 1.0 |
Phylogeny | 2 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Antineoplastic Agents/*chemical synthesis/chemistry/pharmacology | 2 | 7.0 |
DNA Topoisomerases, Type I/*antagonists & inhibitors | 9 | 29.0 |
Drug Screening Assays, Antitumor | 11 | 3.0 |
Mice | 11 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Transfection | 6 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Saccharomyces cerevisiae/enzymology/genetics | 2 | 4.0 |
Inhibitory Concentration 50 | 3 | 1.0 |
Regression Analysis | 2 | 0.0 |
Kinetics | 3 | 0.0 |
Models, Molecular | 3 | 0.0 |
CHO Cells | 4 | 0.0 |
Hamsters | 7 | 0.0 |
Ubiquitins/*metabolism | 2 | 1.0 |
Carbazoles/chemistry/*pharmacology | 2 | 66.0 |
Cell Division/drug effects | 6 | 0.0 |
DNA Topoisomerases, Type I/antagonists & inhibitors/*metabolism | 5 | 62.0 |
Amino Acid Sequence | 8 | 0.0 |
*Mutation | 2 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Simian virus 40/genetics | 2 | 1.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Drug Resistance, Neoplasm | 8 | 1.0 |
Intercalating Agents/pharmacology | 2 | 16.0 |
DNA, Neoplasm/*drug effects | 2 | 16.0 |
Flow Cytometry | 3 | 0.0 |
Isoquinolines/*pharmacology | 2 | 7.0 |
Protein p53/metabolism | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 5 | 0.0 |
DNA/metabolism | 5 | 0.0 |
Camptothecin/*analogs & derivatives/*pharmacology | 2 | 18.0 |
Enzyme Stability/drug effects | 2 | 16.0 |
Point Mutation | 3 | 0.0 |
Drug Stability | 2 | 0.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Hydrolysis | 3 | 0.0 |
Mice, Nude | 4 | 0.0 |
Antineoplastic Agents/pharmacology | 5 | 0.0 |
*DNA Damage | 7 | 1.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Drug Resistance, Microbial/genetics | 2 | 2.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 2 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Translocation, Genetic/*genetics | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
Treatment Outcome | 2 | 0.0 |
*DNA Repair | 2 | 0.0 |
Hela Cells | 5 | 0.0 |
Camptothecin/*analogs & derivatives/pharmacology | 2 | 20.0 |
DNA Primers | 4 | 0.0 |
DNA/*chemistry | 2 | 3.0 |
Drug Resistance | 4 | 0.0 |
Molecular Structure | 3 | 0.0 |
Consensus Sequence | 2 | 0.0 |
Drug Design | 3 | 0.0 |
Substrate Specificity | 5 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Antineoplastic Agents/*chemical synthesis/pharmacology | 2 | 14.0 |
Cell Line, Tumor | 4 | 0.0 |
Enzyme Inhibitors/*chemical synthesis/pharmacology | 2 | 11.0 |
Isoquinolines/*chemical synthesis/pharmacology | 3 | 100.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
*Chromosomes, Human, Pair 20 | 2 | 1.0 |
*Recombination, Genetic | 2 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Oligonucleotides/metabolism | 2 | 2.0 |
DNA Topoisomerases, Type I/biosynthesis/*genetics | 2 | 100.0 |
Nucleic Acid Conformation | 4 | 0.0 |
Transduction, Genetic | 2 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Colonic Neoplasms/*pathology | 2 | 2.0 |
DNA Fragmentation | 2 | 0.0 |
S Phase/drug effects | 2 | 3.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 2 | 2.0 |
DNA Topoisomerases, Type I/*antagonists & inhibitors/genetics/*metabolism | 2 | 100.0 |
DNA Topoisomerases, Type II/metabolism | 2 | 9.0 |
Enzyme Stability | 2 | 1.0 |
In Vitro | 3 | 0.0 |
Ligands | 2 | 0.0 |
Circular Dichroism | 2 | 0.0 |
Nucleic Acid Conformation/drug effects | 2 | 40.0 |
DNA/*metabolism | 3 | 0.0 |
Aphidicolin/pharmacology | 3 | 6.0 |
Drug Resistance, Multiple | 2 | 1.0 |
DNA Topoisomerases, Type I/*genetics/metabolism | 3 | 50.0 |
Conserved Sequence | 2 | 0.0 |
Camptothecin/*toxicity | 3 | 100.0 |
Immunoblotting | 2 | 0.0 |
DNA Topoisomerases, Type I/*antagonists & inhibitors/metabolism | 5 | 62.0 |
DNA Topoisomerases, Type II/*antagonists & inhibitors/metabolism | 2 | 66.0 |
Tyrosine | 2 | 1.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
